<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03282929</url>
  </required_header>
  <id_info>
    <org_study_id>N-A-PH1-15-050</org_study_id>
    <nct_id>NCT03282929</nct_id>
  </id_info>
  <brief_title>Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)</brief_title>
  <official_title>An Single-dose, Open Label, Randomized Cross-over Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose, open label, randomized cross-over study to explore the pharmacokinetics and
      pharmacodynamics of epinephrine in healthy male and female subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single dose, open label, randomized cross-over study to explore the pharmacokinetics and
      pharmacodynamics of epinephrine in healthy male and female subjects with different
      skin-to-muscle depth (STMD) of the thigh after injections with four different marketed
      auto-injectors
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Pharmacokinetics and pharmacodynamics of epinephrine in healthy male and female subjects with different skin-to-muscle depth (STMD) of the thigh after injections with four different marketed auto-injectors</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>14 days</time_frame>
    <description>Maximum observed drug concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>14 days</time_frame>
    <description>Time of the maximum drug concentration (obtained without interpolation). If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Anaphylaxis</condition>
  <arm_group>
    <arm_group_label>Part 1 Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Part 1</intervention_name>
    <description>A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order</description>
    <arm_group_label>Part 1 Group 1</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Part 2 Group 1</intervention_name>
    <description>300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)</description>
    <arm_group_label>Part 2 group 1</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part 2 group 2</intervention_name>
    <description>500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)</description>
    <arm_group_label>Part 2 Group 2</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Part 2 group 3</intervention_name>
    <description>300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)</description>
    <arm_group_label>Part 2 Group 3</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Part 2 Group 4</intervention_name>
    <description>300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)</description>
    <arm_group_label>Part 2 Group 4</arm_group_label>
    <other_name>Group 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female subjects, between 18 and 54 years of age (inclusive).

          2. Subjects who are able and willing to give written informed consent.

          3. Body mass index (BMI) between 28.0 and 40.0 kg/m² (inclusive). Weight on Day -1 may
             not have changed by more than 3 kg compared to screening.

          4. Compressed STMD of 10 mm and above (Part 1+2).

          5. Non-smoker for at least 6 months.

        Exclusion Criteria:

          1. Receipt of medication (prescription or non-prescription) within 14 days prior to the
             planned drug administration, except for occasional use of paracetamol or ibuprofen.

          2. Receipt of any of the following medications within the previous 6 months; beta
             adrenergic blockers, tricyclic antidepressants, monoamine oxidase inhibitors and
             catechol-O-methyl transferase inhibitors, methylphenidate, amphetamines, any drugs
             that may sensitize the heart to arrhythmias, including digitalis and quinidine.

          3. History or current evidence of a clinically significant disease including, but not
             limited to: cardiovascular, hepatic, renal, hematological, neuropsychological,
             endocrine, gastrointestinal or pulmonary diseases especially asthma bronchiale.
             Significant is defined as any disease that, in the opinion of the investigator, would
             put the safety of the subject at risk through participation, or which could affect the
             endpoint analysis if the disease/condition exacerbated during the study.

             History or presence of silent infections, including positive tests for HIV1, HIV2,
             Hepatitis B or C.

          4. Presence of any disease or condition known to interfere with the absorption,
             distribution, metabolism or excretion of drugs.

          5. Hypersensitivity to epinephrine or any of the excipients (e.g. metabisulphite).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>54 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beate Klaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baush and Lomb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natasa Orlic-Pleyer</last_name>
    <phone>+49 30 330 93 - 318</phone>
    <email>natasa.orlic-pleyer@bausch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <state>Wegenerstrasse 13</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Klaus, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anaphylaxis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

